289 related articles for article (PubMed ID: 12689925)
1. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
Terpos E; Szydlo R; Apperley JF; Hatjiharissi E; Politou M; Meletis J; Viniou N; Yataganas X; Goldman JM; Rahemtulla A
Blood; 2003 Aug; 102(3):1064-9. PubMed ID: 12689925
[TBL] [Abstract][Full Text] [Related]
2. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
3. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
4. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
5. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
[TBL] [Abstract][Full Text] [Related]
7. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
Rogers A; Eastell R
J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women.
Hofbauer LC; Schoppet M; Schüller P; Viereck V; Christ M
Clin Endocrinol (Oxf); 2004 Feb; 60(2):214-9. PubMed ID: 14725683
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
Buxton EC; Yao W; Lane NE
J Clin Endocrinol Metab; 2004 Jul; 89(7):3332-6. PubMed ID: 15240611
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
[TBL] [Abstract][Full Text] [Related]
11. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
Crisafulli A; Altavilla D; Squadrito G; Romeo A; Adamo EB; Marini R; Inferrera MA; Marini H; Bitto A; D'Anna R; Corrado F; Bartolone S; Frisina N; Squadrito F
J Clin Endocrinol Metab; 2004 Jan; 89(1):188-92. PubMed ID: 14715848
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Bernstein CN; Sargent M; Leslie WD
Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.
Skoumal M; Kolarz G; Haberhauer G; Woloszczuk W; Hawa G; Klingler A
Rheumatol Int; 2005 Nov; 26(1):63-9. PubMed ID: 15889303
[TBL] [Abstract][Full Text] [Related]
14. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
[TBL] [Abstract][Full Text] [Related]
16. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
[TBL] [Abstract][Full Text] [Related]
17. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
18. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; Apperley JF; Rahemtulla A
Leukemia; 2004 Aug; 18(8):1420-6. PubMed ID: 15215875
[TBL] [Abstract][Full Text] [Related]
20. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]